#Merck inform edc trial
Optimized clinical data management through reusable workflows for easier global clinical trial setup and implementation.The Oracle Health Sciences DMW provides the Accenture Life Sciences Cloud for R&D with several key benefits, including:
Trial sponsors and contract research organizations will now be able to increase the speed and accuracy of data collection, integration and analysis achieve greater efficiency of clinical workflow and query management and accelerate stakeholders’ access to data across the trial lifecycle from source to submission.
#Merck inform edc manual
With the addition of the Oracle Health Sciences DMW, the Accenture Life Sciences Cloud for R&D automates the time-consuming and resource-intensive manual processes required to load, transform and clean trial data. This latest version of the Accenture Life Sciences Cloud for R&D offers the Oracle Health Sciences Data Management Workbench (DMW), which includes prebuilt integrations to the Oracle Health Sciences InForm, an electronic data capture (EDC) solution to create an end-to-end clinical data collection and management platform. This enables life sciences companies to generate high-quality, reliable and statistically sound data from clinical trials to reduce the time, effort and cost needed to take drugs from development to market. 22, 2015 – Accenture (NYSE: ACN) has expanded the Accenture Life Sciences Cloud for Research and Development (R&D) powered by Oracle with the addition of enhanced clinical data management capabilities.
#Merck inform edc update
Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.NEW YORK Apr. The company assumes no duty to update the information to reflect subsequent developments. The information contained in this website was current as of the date presented. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2015 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (No Duty to Update The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Risks and uncertainties include, but are not limited to, general industry conditions and competition general economic factors, including interest rate and currency exchange rate fluctuations the impact of pharmaceutical industry regulation and healthcare legislation in the United States and internationally global trends toward healthcare cost containment technological advances, new products and patents attained by competitors challenges inherent in new product development, including obtaining regulatory approval the company’s ability to accurately predict future market conditions manufacturing difficulties or delays financial instability of international economies and sovereign risk dependence on the effectiveness of the company’s patents and other protections for innovative products and the exposure to litigation, including patent litigation, and/or regulatory actions. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. This website of Merck & Co., Inc., Kenilworth, NJ, USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995.
0 kommentar(er)
